Navigation Links
Celebrex inhibited the burden of skin cancer in high-risk patients
Date:1/4/2010

roup.

In a separate editorial, also published in the January issue of Cancer Prevention Research, Charles M. Rudin, M.D., Ph.D., wrote that "this new study of cyclooxygenase inhibition, together with recent data on the efficacy of the hedgehog pathway inhibition, offer new hope for patients at a high risk for basal cell cancer."

"Basal cell carcinoma is an incredibly common disease, far and away the most common cancer in people. The potential for a therapy that would impact the incidence of this would be huge," said Rudin, associate director for clinical research at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins.

Rudin told the American Association for Cancer Research that while the clinical results of this study do not have an immediate impact for patients with basal cell carcinoma, Epstein and colleagues have set a precedent for future clinical trials.

So how do these findings translate to the clinic?

In another accompanying editorial, also published in the same issue of Cancer Prevention Research, Jack L. Arbiser, M.D., Ph.D., wrote that these results demonstrate a pivotal role in the pathogenesis of basal cell carcinoma and point towards combination therapy among those with this form of cancer.

"This has implications for public health," said Arbiser, professor of dermatology in the Department of Dermatology at Emory University School of Medicine.

Although the results of this study showed positive results in reducing cancer, Epstein suggested that concerns remain about the potential cardiovascular side effects (i.e., stroke or heart attack) that may be associated with this drug. More studies are needed to validate the safety and efficacy of the use of celecoxib in this population.


'/>"/>

Contact: Tara Yates
tara.yates@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert  

Page: 1 2

Related biology news :

1. KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex
2. Poor Americans in the United States suffer hidden burden of parasitic and other neglected diseases
3. NTDs burden in Latin America and the Caribbean may exceed that of HIV/AIDS, TB and malaria
4. Fighting the burden of mental disorders
5. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
6. A study by the MUHC and McGill University opens a new door to understanding cancer
7. ESF EURYI award winner aims to stop cancer cells reading their own DNA
8. Protein chatter linked to cancer activation
9. Newly created cancer stem cells could aid breast cancer research
10. Western diet linked to increased risk of colon cancer recurrence
11. Obesity and lack of exercise could enhance the risk of pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celebrex inhibited the burden of skin cancer in high-risk patients
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint ... FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World Peace ... of FPC,s distributors in Asia . Deliveries ... The sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of approximately 2,200 ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... release is available in Spanish . , Barcelona, ... been discovered that neutrophils exist in the spleen without there ... group on the Biology of B Cells of IMIM (Hospital ... Sinai in New York, has also made it possible to ...
... imaging technologies and their contrast agents chemicals used during ... exposure to radiation or heavy metals, which present potential health ... applied. In an effort to mitigate these drawbacks, new research ... an iron-based contrast agent so that it only interacts with ...
... Calif., December 23, 2011 John C. Reed, M.D., Ph.D., ... Institute (Sanford-Burnham), have been named as Fellows of the American ... AAAS Fellow is an honor bestowed upon AAAS members by ... announced today in the AAAS News & Notes section of ...
Cached Biology News:Discovered the existence of neutrophils in the spleen 2Penn engineers develop more effective MRI contrast agent for cancer detection 2Penn engineers develop more effective MRI contrast agent for cancer detection 3AAAS and Sanford-Burnham announce 2011 fellows 2
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
(Date:7/29/2015)... 2015  HealthSouth Corporation (NYSE: HLS ... post-acute healthcare services, offering both facility-based and home-based ... for the second quarter ended June 30, 2015. ... strong volume growth in both segments and an ... Grinney, President and Chief Executive Officer of HealthSouth. ...
(Date:7/29/2015)... 29, 2015 Research ... addition of the "Global Biosimilars Market, 2015 ... The Global Biosimilars Market, 2015 - 2025, ... growing biosimilars market. With the blockbuster biologics losing ... costs, biosimilars are being viewed as viable substitutes ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27
... , CALGARY and BLENHEIM, Ontario, Nov. 24 ... assets of Hyland Seeds, a division of Thompsons Limited of ... Dow AgroSciences, current seeds business as the company anticipates the ... and Dow AgroSciences Herbicide Tolerant Trait Technology in corn ...
... ... deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced the approval of all of ... Delaware,(the "Bankruptcy Court"). deCODE last week filed a voluntary petition for,relief under ... The orders issued by the Bankruptcy Court allow ...
... , SEATTLE, Nov. 24 Blue Marble Energy Corp. ... Development Authority (OPDA) were recently awarded $2 million by ... private/public partnership to construct the state,s first specialty biochemical ... investment will significantly speed the development of our biorefinery ...
Cached Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...
CMRL Medium-1066 (1X) liquid...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
... The PowerEase 500 Power Supply ... electrophoresis. It offers extensive programming ... four custom methods for you ... preferences. The simple intuitive PowerEase ...
Biology Products: